Nevisense

Stockholm – October 15, 2026 -- The US National Institutes of Health (NIH) has selected SciBase Holding AB's Nevisense electrical impedance spectroscopy (EIS) technology as the primary endpoint in its THREAT study, which will test how environmental exposures affect the skin barrier in 80 healthy volunteers.

NIH and Swiss institute launch THREAT study on everyday exposures

THREAT (Testing Harms Related to Exposure to Allergenic Toxins) is led by the NIH in collaboration with the Swiss Institute of Allergy and Asthma Research (SIAF). The study design is described in an editorial in the peer-reviewed journal Allergy, titled "Exploring the Link Between Environmental Exposures and Disease via Direct Challenge."

Stockholm – October 14, 2026 -- SciBase Holding AB (STO: SCIB) has received its first positive medical policy for Nevisense from Highmark Blue Cross Blue Shield, which serves more than 7 million members across multiple US states. The decision moves eligible use of the skin-lesion device from a predominantly cash-pay model into covered care through a major private insurer.

Highmark policy applies to all commercial lines and opt-in self-funded groups

Highmark considers electrical impedance spectroscopy (EIS) medically necessary when a dermatologist is evaluating a clinically atypical suspicious pigmented lesion and is considering a biopsy. The procedure is reported under CPT code 0658T. The policy covers all Highmark commercial insured lines of business and self-funded (ASO) employer groups that elect it.

Coverage is limited to defined cases:

Stockholm – October 07, 2026 -- SciBase Holding AB has recalculated the terms of its series TO 2 warrants following a rights issue of shares resolved by its board on September 3, 2026, cutting the subscription ratio to 0.01 shares per warrant.

Subscription price drops to SEK 37.47 per share under new warrant terms

Each TO 2 warrant now entitles the holder to subscribe for 0.01 new shares at SEK 37.47 per share, down from the original terms set when the instrument was issued alongside SciBase's April 2024 capital raise. The adjustment follows contractual provisions requiring recalculation of warrant terms whenever the company conducts a subsequent rights issue.

Stockholm – October 01, 2026 -- SciBase Holding AB has closed its rights issue fully subscribed, raising approximately SEK 57.5 million before issue costs to fund continued commercialisation of its Nevisense melanoma-diagnostics platform in the United States.

Shareholders cover nearly three-quarters of the offering

The subscription period, which ran through 29 September 2026, saw 2,681,085 shares subscribed with the support of subscription rights, equal to roughly SEK 40.2 million, or 69.9 percent of the issue. An additional 133,116 shares were subscribed without subscription rights, adding SEK 2.0 million, or 3.5 percent. In total, 2,814,201 shares were subscribed with and without rights, covering approximately SEK 42.2 million, or 73.4 percent of the SEK 57.5 million target.

Stockholm – September 25, 2026 -- SciBase Holding AB's SEK 57.5 million rights issue is now fully covered after Bergs Securities AB confirmed a binding guarantee commitment of approximately SEK 24.2 million, equal to 42 percent of the offering.

Guarantee commitment converts letter of intent into binding coverage

Bergs Securities fulfilled on September 25, 2026, a guarantee intention it first announced on September 3, 2026, by delivering a formal guarantee confirmation to SciBase. The firm has backed the commitment with sub-guarantee agreements from a consortium of investors covering the full guaranteed amount.

Stockholm – September 18, 2026 -- SciBase Holding AB has pushed back the first day of trading in subscription rights and paid subscribed shares (BTA) tied to its ongoing rights issue by one day, moving the start date from September 18, 2026 to September 18, 2026 on Nasdaq First North Growth Market.

The subscription period itself remains unchanged, running from September 15 through September 18, 2026.

Timetable shift leaves subscription window intact

The Swedish medtech company confirmed the updated timetable applies only to the trading commencement of subscription rights and BTAs, not to the underlying subscription mechanics of the capital raise.

Michael Colérus, Chief Financial Officer of SciBase, is the designated contact for investor inquiries related to the adjustment.